55837-18-8 Usage
Uses
Used in Pharmaceutical Industry:
Butibufen is used as an anti-inflammatory and analgesic agent for the treatment of rheumatologic conditions. Its application is based on its effectiveness in managing pain and inflammation associated with conditions such as osteoarthritis. The drug's faster onset of action and reduced side effects make it a preferred choice for patients suffering from these conditions.
Used in Pain Management:
Butibufen is also used in pain management, particularly for individuals experiencing moderate to severe pain. Its analgesic properties make it a suitable option for those in need of relief from various types of pain, including chronic and acute pain conditions.
Used in Research and Development:
In addition to its clinical applications, Butibufen is utilized in research and development for the study of anti-inflammatory and analgesic drug mechanisms. Its unique properties and effectiveness in treating rheumatologic conditions make it a valuable compound for further investigation and potential development of new therapeutic agents.
Originator
Juste (Spain)
Manufacturing Process
1st method:4-Isobutylphenylbenzyl chloride was prepared by passing a stream of
hydrogen chloride into a suspension of p-bromoaldehyde and anhydrous zinc
chloride in isobutylbenzene. A mixture of 137 g (0.75 mol) of 4-isobutylbenzyl
chloride thus prepared, 44.1 g (0.90 mol) of sodium cyanide, 216 g of 99%
ethanol, and 81.3 g of water was heated refluxed for 6 hours. The mixture
became reddish-black in color. From this mixture, 215 ml of ethanol and water was then distilled and the residue was filtered. The solids that were separated
by filtration were washed with 100 ml of diethyl ether and the ether washings
were combined with the original filtrate, to which 800 ml of water was then
added. The organic phase was then separated from the aqueous phase,
washed with five 400 ml portions of water and dried over anhydrous sodium
sulfate. The ether was evaporated from the dried organic phase by vacuum
distillation and the residue which distilled between 130°C and 132°C at a
pressure of 7 mm of mercury was collected. The yields of 4-isobutylbenzene
cyanide 100-113 g.To a solution of 6.7 g of sodium amide in 100 ml of anhydrous diethyl ether
was added dropwise 26 g of 4-isobutylbenzene cyanide while the mixture was
stirred and heated under gentle reflux. After all of the 4-isobutylbenzene
cyanide had been added, the mixture was heated under gentle reflux for 15
min, after which 23.4 g of ethyl iodide was slowly added dropwise thereto
from the dropping funnel. After completion of the addition of the ethyl iodide,
the mixture was heated under gentle reflux for an initial period of 15 min,
after which it was diluted with an equal volume of water and shaken. The two
layers that formed were separated and the aqueous layer was then extracted
with two 50 ml portions of diethyl ether. The ether extracts were combined
and then washed with two 80 ml portions of water and dried over anhydrous
magnesium sulfate. The dried ether extract was then distilled at a
subatmospheric pressure. In this manner, 25 g of a clear transparent
uncolored liquid having a boiling point of 118-122°C at a pressure of 1mm of
mercury, which consisted of 2-(4-isobutylphenyl)butyronitrile, was collected.
This yield was equivalent to 83% of the theoretical.A mixture of 40 g (0.2 mol) of 2-(4-isobutylphenyl)butyronitrile and 78 ml of
a freshly prepared solution of sodium hydroxide that was prepared by
dissolving 28 g of sodium hydroxide in 25 ml of distilled water and the volume
of which was brought to 100 ml by addition thereto of methanol, was heated
under gentle reflux in a flask provided with a stirrer and reflux condenser
while the mixture was stirred during a period of 9 hours. From the mixture
the methanol and a portion of the water were distilled and the mixture was
then cooled, the crystals began to separate. The mixture was then diluted
with 150 ml of water and extracted with two 25 ml portions of diethyl ether.
The remaining aqueous solution containing the sodium salt of 2-(4-
isobutylphenyl)butyric acid was then saturated with sodium chloride until the
salt started to precipitate. The solution was then cooled to 5°C and the
precipitated salt was separated by filtration, recrystallized from isopropanol,
and dried in a vacuum desiccator at a pressure of 1 mm of mercury until it
had attained a constant weight. In this manner, 32 g of sodium 2-(4-
isobutylphenyl)butyrate having a melting point of 188-191°C, which is
equivalent to a yield of 67% of the theoretical, was obtained.Dilute hydrochloric acid (19% by weight of hydrogen chloride) was slowly
added to a cold solution of 25 g of the sodium 2-(4-isobutylphenyl)butyrate
thus prepared in 100 ml of water until the solution corresponded to pH of 1.0.
The oil which precipitated was then allowed to solidify to a white solid by
standing in a refrigerator. The white solid was then separated by filtration,
dried, and recrystallized from petroleum ether. It had a melting point of 50-
52°C, and its elementary analysis corresponded to the 2-(4-
isobutylphenyl)butyric acid.2nd method:5.0 g of small pellets of sodium metal were added slowly with stirring to 150
ml of absolute ethanol, while a current of nitrogen gas was passed there
through so as to blanket the solution from the atmosphere. After all of the
sodium metal had been dissolved and while the solution was maintained at a
temperature of 50°C, a solution of 52 g of ethyl 2-(4-
isobutylphenyl)cyanoacetate in 50 ml of absolute ethanol was added dropwise
while the mixture was stirred. Subsequently, 81 g of ethyl iodide was
gradually added to the mixture with stirring, after which the introduction of
nitrogen gas into the mixture was discontinued and the mixture was heated
for a period of 2.5 hours under gentle reflux. Thereafter, the ethanol and
excess ethyl iodide were distilled from the mixture and the residue was then
diluted with three times its volume of water and shaken therewith. The 2-(4-
isobutylphenyl)-2-(ethoxycarbonyl)butyronitrile was then extracted from the
mixture with three 50 ml portions of diethyl ether, the extracts were
combined, washed with a 20% aqueous solution of sodium bisulfate and dried
over anhydrous magnesium sulfate. The ether was then expelled from the
extract by distillation and the residue was distilled at a subatmospheric
pressure, yielding 45 g of a fraction containing 2-(4-isobutylphenyl)-2-
(ethoxycarbonyl)butyronitrile having a boiling point of 150-155°C/3 mm of
mercury (78% of the theoretical yield).In a 2-liter flask provided with a stirrer and reflux condenser a solution of 129
g of 2-(4-isobutylphenyl)-2-(ethyoxycarbonyl)butyronitrile in 980 ml of a 20%
solution of potassium hydroxide in methanol was heated with stirring at 40°C
for a period of 1 hour. The mixture was then heated under gentle reflux with
stirring for an additional period of 3 hours, during which a white solid
precipitated. This mixture was then poured into 1.5 liters of water and
acidified with an aqueous solution of hydrochloric acid (concentrated
hydrochloric acid diluted with an equal volume of water) to a hydrogen ion
concentration corresponding to a pH of 2.5, while carbon dioxide was evolved
therefrom. The aqueous mixture was then extracted with diethyl ether. The
extracts were washed successively with a saturated solution of sodium
bicarbonate and water, dried over anhydrous magnesium sulfate, and distilled
at a subatmospheric pressure, to yield 86.5 g of a fraction consisting of 2-(4-
isobutylphenyl)butyronitrile having a boiling point of 124-128°C at a pressure
of 1.5 mm of mercury, which is equivalent to approximately 0.43 mol and a
yield of 91% of the theoretical based on the original 2-(4-isobutylphenyl)-2-
(ethoxycarbonyl)butyronitrile.The 2-(4-isobutylphenyl)butyronitrile was converted to sodium 2-(4-
isobutylphenyl)butyrate and subsequently to 2-(4-isobutylphenyl)butyric acid
in the same manner as described in Method 1 hereinbefore.
Therapeutic Function
Antiinflammatory, Analgesic
Check Digit Verification of cas no
The CAS Registry Mumber 55837-18-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,8,3 and 7 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 55837-18:
(7*5)+(6*5)+(5*8)+(4*3)+(3*7)+(2*1)+(1*8)=148
148 % 10 = 8
So 55837-18-8 is a valid CAS Registry Number.
InChI:InChI=1/C14H20O2/c1-4-13(14(15)16)12-7-5-11(6-8-12)9-10(2)3/h5-8,10,13H,4,9H2,1-3H3,(H,15,16)
55837-18-8Relevant articles and documents
Caesium fluoride-mediated hydrocarboxylation of alkenes and allenes: Scope and mechanistic insights
Gevorgyan, Ashot,Obst, Marc F.,Guttormsen, Yngve,Maseras, Feliu,Hopmann, Kathrin H.,Bayer, Annette
, p. 10072 - 10078 (2019/11/14)
A caesium fluoride-mediated hydrocarboxylation of olefins is disclosed that does not rely on precious transition metal catalysts and ligands. The reaction occurs at atmospheric pressures of CO2 in the presence of 9-BBN as a stoichiometric reductant. Stilbenes, β-substituted styrenes and allenes could be carboxylated in good yields. The developed methodology can be used for preparation of commercial drugs as well as for gram scale hydrocarboxylation. Computational studies indicate that the reaction occurs via formation of an organocaesium intermediate.
Process for preparing α-hydroxy-acids and compounds obtained by this process
-
, (2008/06/13)
The invention relates to a process for preparing α-hydroxy-acids of general formula: STR1 in which R represents hydrogen or a lower alkyl radical and Cy represents a phenyl, naphthyl or heterocyclic radical, these latter three radicals optionally comprising one or more substituents selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy radicals and halogen atoms, process which comprises the treatment of an α-monohalogenated ketone of general formula: STR2 in which R and Cy have the same meaning as above and X represents chlorine, bromine or iodine, in the presence of an aqueous solution of an alkali metal hydroxide, a non-polar organic solvent selected from an aromatic or alicyclic hydrocarbon and oxygen in excess optionally in the presence of an inert gas, the treatment being carried out at a temperature ranging from the boiling temperature of the reaction medium at atmospheric pressure and 240° C. under pressure and the alkali metal so formed is then acidified to obtain the desired acid.
Process for preparing α-hydroxy-alkanoic acids and compounds obtained by this process
-
, (2008/06/13)
The invention relates to a process for preparing α-hydroxy-alkanoic acids of general formula: STR1 in which R represents hydrogen or a lower alkyl radical and Cy represents phenyl or a heterocyclic radical, both radicals optionally comprising one or more substituents selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl radicals and halogen atoms, process which comprises the treatment of an α,α-dihalogenated ketone of general formula: STR2 in which R and Cy have the same meaning as above and X represents chlorine, bromine or iodine, in the presence of an aqueous solution of an alkali metal hydroxide and a non polar organic solvent selected from an aromatic or alicyclic hydrocarbon, the treatment being carried out at a temperature between the boiling temperature of the reaction medium at atmospheric pressure and 240° C. under pressure and the alkali metal so formed is then acidified to obtain the desired acid.
Phenylalkanoic compounds and therapeutic use thereof
-
, (2008/06/13)
Novel phenylalkanoic compounds of the formula I STR1 wherein R1 and R2 independently from each other represent hydrogen or alkyl with 1 to 8 carbon atoms, salts of such compounds and salts thereof, therapeutic uses of the phenylalkanoic compounds, or of the pharmacologically safe salts thereof for treating inflammatory diseases, tussive states, pain symptoms and pyretic diseases and pharmaceutical composition containing the phenylalkanoic compounds or the pharmacologically safe salts together with a carrier and an optional adjuvant or additive.
Esters and amides containing the 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetyl moiety
-
, (2008/06/13)
Compounds of the formula STR1 wherein each X, which may be identical or different from the other X, is oxygen or imino; R1 is hydrogen, fluorine, chlorine or bromine; R2 and R3, which may be identical or different from each other, are each hydrogen; unsubstituted or mono-substituted alkyl of 1 to 6 carbon atoms, where the substituent is phenyl or dialkylamino with 1 to 3 carbon atoms in each alkyl moiety; pyridyl; or cycloalkyl of 5 to 7 carbon atoms; R2 and R3, together with each other and the nitrogen atoms to which they are attached, are pyrrolidino, piperidino, hexamethyleneimino, morpholino, N-aryl-piperazino or N-(alkyl of 1 to 3 carbon atoms)-piperazino; A is cycloalkylene of 5 to 7 carbon atoms; unsubstituted or substituted alkylene of 2 to 10 carbon atoms, where the substituents are one to two alkyls of 1 to 3 carbon atoms each, one to two carbalkoxys of 2 to 4 carbon atoms each, one to two phenyls, one to four hydroxyls, one halomethyl, one hydroxymethyl, one alkanoyloxy of 1 to 18 carbon atoms, one alkanoyloxymethyl of 1 to 18 carbon atoms in the alkanoyl moiety or one STR2 where R1, R2 and R3 have the meanings previously defined; or alkylene of 2 to 10 carbon atoms interrupted by oxygen, sulfur, sulfoxide, sulfonyl, phenyl, cyclohexyl, pyridyl, piperazino or unsubstituted or substituted imino, where the substituent on the imino group is alkyl of 1 to 6 carbon atoms, phenyl or phenylalkyl of 1 to 3 carbon atoms in the alkyl moiety; B is the acyl residue of an antiphlogistic carboxylic acid; and their non-toxic, pharmacologically acceptable acid addition salts. The compounds as well as their salts are useful as anti-inflammatories.
2-(4-Isobutyl phenyl)butyric acid, salts thereof, and pharmaceutical compositions containing the same
-
, (2008/06/13)
2-(4-Isobutylphenyl)butyric acid and pharmaceutically acceptable salts thereof, processes for their production, and pharmaceutical compositions containing the same are disclosed. The compounds have antiinflammatory, analgesic and antipyretic properties.
